Generic Copaxone is coming

Share this article:

Teva's push to keep generic Copaxone off the market its over. Bloomberg reports the company lost its suit to keep generics at bay, just 10 days before the expiration of the branded MS drug's patent.

Teva wanted more testing of generic versions of the drug, but a federal judge said forget it.

The company has prepped investors for the possibility that its major drug could get competition this year, and even went so far as to provide two 2014 forecasts: one in which Copaxone had the market to itself, and other in which it did not.

Despite generics concern, the company has been able to convert Copaxone users to a newer, patent-protected formulation.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies